Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Nanoparticles

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    26 result(s) found for: Nanoparticles. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2020-004552-15 Sponsor Protocol Number: NANO-GBM Start Date*: 2021-03-18
    Sponsor Name:Centre Jean Perrin
    Full Title: Phase I/II study of AGuIX nanoparticles with radiotherapy plus concomitant Temozolomide in the treatment of newly diagnosed glioblastoma
    Medical condition: glioblastoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-003994-80 Sponsor Protocol Number: ET18-270 Start Date*: 2019-10-03
    Sponsor Name:Centre Léon Bérard
    Full Title: A Phase II study evaluating AGuIX® nanoparticles in combination with Stereotactic Radiation for oligo brain metastases
    Medical condition: Brain metastases
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10006128 Brain metastases LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-003671-17 Sponsor Protocol Number: NANOPRO Start Date*: 2021-02-15
    Sponsor Name:Centre François Baclesse
    Full Title: Nanoparticle reirradiation and hypofractionated protontherapy of pan-tumor relapse: non-randomized phase II study.
    Medical condition: recurrent tumors
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038111 Recurrent cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-000724-10 Sponsor Protocol Number: 60978 Start Date*: 2018-07-04
    Sponsor Name:Academic Medical Center
    Full Title: Targeting esophageal cancer with HDL nanoparticles: an imaging study
    Medical condition: Primary esophageal cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-005459-41 Sponsor Protocol Number: ferucarbotran in Pz. con melanoma Start Date*: 2007-09-17
    Sponsor Name:AZIENDA OSPEDALIERA DI PADOVA
    Full Title: Study of superficial lynmph nodes whit superparamagnetic contrast and RMN in patient affected by melanoma.
    Medical condition: melanomas of limbs.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025650 Malignant melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-004567-29 Sponsor Protocol Number: RADSIN1 Start Date*: 2004-11-22
    Sponsor Name:IST - ISTITUTO NAZIONALE PER LA RICERCA SUL CANCRO
    Full Title: Pelvic lymph node metastases from bladder and prostate cancer magnetic resonance imaging with ultrasmall superparamagnetic iron oxyde sinerem.
    Medical condition: SUSPECT LYMPHONODAL METASTASES
    Disease: Version SOC Term Classification Code Term Level
    6.1 10036909 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001688-20 Sponsor Protocol Number: AGO/2017/003 Start Date*: 2017-08-25
    Sponsor Name:Ghent University Hospital
    Full Title: INTRAPERITONEAL AEROSOLISATION OF ALBUMIN-STABILIZED PACLITAXEL NANOPARTICLES FOR PERITONEAL CARCINOMATOSIS – PHASE I/II STUDY PROTOCOL
    Medical condition: peritoneal carcinomatosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2017-001172-36 Sponsor Protocol Number: DX211 Start Date*: 2017-08-09
    Sponsor Name:Oculis ehf.
    Full Title: Efficacy and safety of dexamethasone nanoparticles eye drops in diabetic macular edema.
    Medical condition: Diabaetic macular edema
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10012662 Diabetic eye disease NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed) FI (Completed) HU (Completed) LV (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2018-001879-20 Sponsor Protocol Number: 38RC18.085 Start Date*: 2018-07-30
    Sponsor Name:Grenoble Alps University Hospital
    Full Title: Radiotherapy of multiple brain metastases using AGuIX® gadolinium-chelated polysiloxane based nanoparticles: a prospective randomized phase II clinical trial.
    Medical condition: Patients with brain metastases, from a histologically confirmed solid tumor, eligible for WBRT
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10006128 Brain metastases LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-001093-16 Sponsor Protocol Number: DX203 Start Date*: 2013-07-16
    Sponsor Name:Oculis ehf.
    Full Title: Comparison of non-MMC trabeculectomy and dexamethasone nanoparticles eye drops with MMC trabeculectomy and Maxidex®
    Medical condition: Anti-inflammatory treatment post trabeculectomy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IS (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-002531-56 Sponsor Protocol Number: COVICO Start Date*: 2022-12-28
    Sponsor Name:Sciensano
    Full Title: LONGITUDINAL FOLLOW-UP OF SARS-COV-2 (COVID-19) IMMUNITY IN IMMUNOCOMPROMISED POPULATIONS IN BELGIUM (COVICO) A non-commercial multicenter academic prospective cohort study during 2023-2026
    Medical condition: Healthy persons and immunocompromised patients (nursing home residents, dialysis patients and kidney- and lung transplant patients) from age 18 till age 105
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-003774-32 Sponsor Protocol Number: N/A Start Date*: 2022-01-26
    Sponsor Name:DIPARTIMENTO BIOMEDICINA E PREVENZIONE UNIVERSITà DEGLI STUDI DI ROMA TOR VERGATA
    Full Title: Enhancing Treatment in Persistent Glioblastoma through AGuIX Nanoparticles for Precision Radiotherapy (NanoGBM-Precision): A Phase II, monocenter, open-label, single-arm, no-profit clinical trial.
    Medical condition: Persistent Glioblastoma Multiforme, grade IV
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-003934-28 Sponsor Protocol Number: SPON1455-15 Start Date*: 2016-03-04
    Sponsor Name:Cardiff University
    Full Title: Enhanced Epidermal Antigen Specific Immunotherapy trial -1 (EE-ASI-1): A Phase 1a study of gold nanoparticles administered intradermally by microneedles to deliver immunotherapy with a proinsulin d...
    Medical condition: Type 1 diabetes
    Disease: Version SOC Term Classification Code Term Level
    18.1 10027433 - Metabolism and nutrition disorders 10067584 Type 1 diabetes mellitus PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2021-003779-32 Sponsor Protocol Number: NL77171.091.21 Start Date*: 2021-09-27
    Sponsor Name:Radboud University Medical Center
    Full Title: HYPo-fractionated Radiotherapy of Lymph Node Metastases guided by NanO-MRI in Prostate Cancer Patients: A Pilot Study (HYPNO-study).
    Medical condition: men with biochemical recurrent prostate cancer after radical prostatectomy with ≤ 4 foci harbouring regional lymph node metastases (up to 6 lymph nodes in total) on nano-MRI.
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-005223-21 Sponsor Protocol Number: D926PC00001 Start Date*: 2022-06-16
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase 3, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator’s Choice of Chemotherapy in Patients who are not Candidates for PD-1/PD-L1 Inhibitor Therapy in Firs...
    Medical condition: Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) IT (Ongoing) DE (Trial now transitioned) BE (Ongoing) HU (Ongoing) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-004493-26 Sponsor Protocol Number: D9670C00001 Start Date*: 2020-09-02
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) versus Investigator’s Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Breast Cancer Patients whose...
    Medical condition: HER2-Low, Hormone Receptor Positive Breast Cancer which has Progressed on Endocrine Therapy in the Metastatic Setting.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing) DK (Ongoing) NL (Ongoing) HU (Ongoing) PL (Ongoing) DE (Ongoing) BE (Ongoing) FR (Ongoing) GB (GB - no longer in EU/EEA) IT (Ongoing) PT (Ongoing) AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-004231-23 Sponsor Protocol Number: 274948 Start Date*: 2020-05-29
    Sponsor Name:Queen Mary University of London
    Full Title: Phase IIb randomised clinical trial repurposing ATRA as a stromal targeting agent in a novel drug combination for pancreatic cancer
    Medical condition: Pancreatic cancer - locally advanced
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10033604 Pancreatic cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2018-003665-34 Sponsor Protocol Number: INP20-01 Start Date*: 2019-04-26
    Sponsor Name:InnoUP Farma SL
    Full Title: A multicenter double-blind, randomized, placebo-controlled phase I/II study to determine the safety, tolerability, potential efficacy and dose finding of INP20, an oral formulation for treatment of...
    Medical condition: Peanut allergy
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004870 10034202 Peanut allergy LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-006181-42 Sponsor Protocol Number: RAD_USPALS_01 Start Date*: 2007-03-15
    Sponsor Name:UMC St Radboud
    Full Title: The use of USPIO enhanced MRI in the assessment of axillary lymph node status in patients with invasive breast cancer
    Medical condition: The presence of axillary metastasis in patients with proven invasive breast cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10006188 Breast cancer female NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-000214-37 Sponsor Protocol Number: Wallstrength_01 Start Date*: 2007-08-07
    Sponsor Name:UMC St Radboud
    Full Title: Biological and biochemical markers of aneurysm wall degradation; towards non-invasive wall strength analysis.
    Medical condition: Abdominal aortic aneurysms. Biomarkers related to diminished aneurysm wall strength.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000051 Abdominal aneurysm LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 22:26:29 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA